IDSA Updates Guidance on Invasive CRAB Treatment
The IDSA now prioritizes sulbactam-durlobactam as the default therapy for invasive carbapenem-resistant A. baumannii infections.
Updated on Oct. 27, 2026 in COVID-19
Live Poll
Do you trust that your local hospital has rapid access to the latest medical treatment recommendations?
On July 30, 2026, the Infectious Diseases Society of America released updated clinical guidance for managing antimicrobial-resistant gram-negative infections. This update shifts the clinical approach to prioritize sulbactam-durlobactam as the preferred treatment target for invasive carbapenem-resistant Acinetobacter baumannii (CRAB) infections.
Why it matters
This update aims to shift treatment strategies away from older, less effective options toward a targeted therapy designed specifically to address the resistance mechanisms of the CRAB organism. By establishing a new default regimen, the guidance seeks to improve patient survival and reduce treatment-related complications for those facing these difficult infections.
In the phase 3 ATTACK trial involving 181 patients, sulbactam-durlobactam demonstrated a 19% 28-day all-cause mortality rate compared to 32% with colistin. Additionally, nephrotoxicity occurred in 13% of recipients, significantly lower than the 38% observed in colistin patients.
The players
Infectious Diseases Society of America
This is a professional medical association that represents physicians and scientists who specialize in the field of infectious diseases.
Food and Drug Administration
This federal agency is responsible for protecting public health by regulating the safety, efficacy, and security of human drugs and biological products.
The details
The new standard of care combines sulbactam-durlobactam with a carbapenem for patients suffering from invasive CRAB infections. For cases where isolates show resistance to this combination, clinicians are advised to utilize two non-sulbactam agents or supplement cefiderocol with sulbactam-durlobactam as a bridge therapy.
Timeline
2023: The FDA approved sulbactam-durlobactam for specific bacterial pneumonia cases.
2024: The previous version of the IDSA antimicrobial-resistant infection guidance was released.
July 30, 2026: The IDSA published the updated antimicrobial-resistant gram-negative infection guidance.
October 2026: IDWeek 2026 was held in Washington, DC.
The Big Picture
The IDSA update on CRAB treatment follows the clinical outcomes established by the phase 3 ATTACK trial. The update codifies into standard practice the superior efficacy and safety profile demonstrated by the phase 3 ATTACK trial.
The new guidance standardizes a more effective treatment regimen for patients with invasive CRAB, potentially reducing the risk of mortality and kidney-related side effects. Patients should consult with their healthcare providers regarding how these updated protocols influence current hospital-based treatment plans for bacterial pneumonia.
The takeaway
The transition to sulbactam-durlobactam as a primary therapy marks a significant update in how clinicians manage resistant bacterial infections. These findings highlight the importance of utilizing targeted drug therapies to reduce systemic toxicity compared to older, less specific antibiotic treatments.
Further reading
For more information on current treatment protocols, visit the COVID-19 section.
More information
Review the full IDSA antimicrobial-resistant infection guidance for detailed clinical recommendations.
Source note: This article includes information reported by Contagionlive.
Live Poll
Do you trust that your local hospital has rapid access to the latest medical treatment recommendations?
